Biotech | February 17, 2022
PerkinElmer’s SIRION Biotech and CRG to develop diabetes gene therapy
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers
Funding to grow the insurance and digital therapeutics vertical in India
The funds will be used to expand digital product offerings, grow their online customer base, and launch their flagship clinic in Bengaluru
TRIS AMINO HCl is widely used as a diagnostic reagent and as a downstream processing buffer in the purification of commercial biopharmaceuticals
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
Subscribe To Our Newsletter & Stay Updated
